New drug cocktail shows promise for Tough-to-Treat recurrent cancers
NCT ID NCT02208375
First seen Nov 06, 2025 · Last updated Apr 29, 2026 · Updated 19 times
Summary
This study tests two drug combinations (olaparib plus either vistusertib or capivasertib) in people with endometrial, triple-negative breast, ovarian, or related cancers that returned after prior treatment. The main goal is to find the safest dose and understand side effects. About 159 adults will take part, and the drugs work by blocking enzymes that help cancer cells grow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.